303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parte...
18 Huhti 202431min
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar d...
11 Huhti 202424min
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest ...
4 Huhti 202431min
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the l...
28 Maalis 202434min
299: Live! From the STAT Breakthrough Summit East
Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientis...
21 Maalis 202433min
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life...
14 Maalis 202435min
297: VC turmoil, GLP-1 competition, & the war on recovery
For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sec...
7 Maalis 202427min
296: Legal insider trading, booming biotech stocks, & the next GLP-1
We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a bann...
29 Helmi 202424min
